Seres Therapeutics
MCRB
134 hedge funds and large institutions have $256M invested in Seres Therapeutics in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 30 reducing their positions, and 23 closing their positions.
551% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $1.03M
77% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.2% less ownership
Funds ownership: 4.39% → 4.19% (-0.2%)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
2% less funds holding
Funds holding: 137 → 134 (-3)
53% less capital invested
Capital invested by funds: $538M → $256M (-$282M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.6M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$4.27M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.7M |
| 4 |
BlackRock
New York
|
+$1.68M |
| 5 |
Citigroup
New York
|
+$877K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$12.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.21M |
| 3 |
Jennison Associates
New York
|
-$6.67M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.49M |
| 5 |
Millennium Management
New York
|
-$3.71M |
MCRB Hedge Fund Activity: Q3 2023 in Review
134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2023, worth a combined $256M — down 53% from $538M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MCRB and 21 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 53 added.
The largest buyer was Point72 Asset Management, adding an estimated $6.6M. The largest seller was Janus Henderson Group, cutting an estimated $12.4M.
- 134 institutional investors held Seres Therapeutics (MCRB) as of Q3 2023, down from 137 in Q2 2023.
- Funds reported $256M of Seres Therapeutics stock for Q3 2023, down 53% quarter-over-quarter.
- 21 funds opened new Seres Therapeutics positions in Q3 2023 and 23 closed out, a net change of -2 holders.
- The largest Seres Therapeutics buyer in Q3 2023 was Point72 Asset Management, an estimated $6.6M added.
- The largest Seres Therapeutics seller in Q3 2023 was Janus Henderson Group, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2023.